CoronaVac

A large phase 3 trial in Brazil found that two doses of CoronaVac, administered 14 days apart, had a 51 percent efficacy against symptomatic SARS-CoV-2 infection, a 100 percent efficacy against severe COVID-19, and a 100 percent efficacy against hospitalization beginning 14 days following the second dose.

In an observational trial, the estimated efficiency of Sinovac-CoronaVac against symptomatic infection in health professionals in Manaus, Brazil, where P.1 accounted for 75% of SARS-CoV-2 samples was 49.6 percent. In the presence of P1 circulation, effectiveness was also demonstrated in observational research conducted in Sao Paulo (83 percent of samples).

Assessments in areas where the P.2 Variant of Concern was widely circulating indicated vaccination efficacy at 49.6 percent after at least one dose and 50.7 percent two weeks later.

MORE INFORMATION:
Manufacturer: Sinovac Biotech Ltd.
Number of Shots: 2 shots, 14 to 28 days apart
Type of Vaccine: Inactivated